XTL Biopharmaceuticals Ltd. (XTLB)

NASDAQ: XTLB · Real-Time Price · USD
1.270
+0.060 (4.96%)
At close: Mar 28, 2025, 4:00 PM
1.205
-0.065 (-5.10%)
After-hours: Mar 28, 2025, 4:27 PM EDT
4.96%
Market Cap 10.97M
Revenue (ttm) 46,000
Net Income (ttm) -1.06M
Shares Out 881.39M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,227
Open 1.254
Previous Close 1.210
Day's Range 1.150 - 1.280
52-Week Range 1.090 - 3.480
Beta 1.07
Analysts n/a
Price Target n/a
Earnings Date May 19, 2025

About XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 1, 2005
Employees 7
Stock Exchange NASDAQ
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial Statements

News

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company  developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 ...

8 months ago - GlobeNewsWire

XTL Entered Definitive Agreement to Acquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company  developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Plac...

10 months ago - GlobeNewsWire

XTL To Aquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Place...

1 year ago - GlobeNewsWire

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...

1 year ago - GlobeNewsWire

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...

1 year ago - GlobeNewsWire